This publication is a summary of a recent webinar. The prevalence of cardiometabolic comorbidities in people with mental illness is high. Professor Hopwood presented guidelines and studies that clearly emphasise the need to manage comorbidities such as obesity in people with serious mental illness. CONTRAVE® is one of four MEDSAFE-approved weight-loss medicines in New Zealand that is well tolerated and effective in weight management. This write up was supported by an educational grant from Radiant Health.
Please login below to download this issue (PDF)